STOCK TITAN

Harmony Biosciences (HRMY) director granted 21,231 stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Harmony Biosciences Holdings, Inc. director Germano Geno J received a grant of stock options as equity compensation. The award covers 21,231 options for common stock at an exercise price of $30.76 per share and expires on May 14, 2036. These options vest in 36 equal monthly installments beginning on June 14, 2026. Following this grant, he holds 21,231 stock options directly, with no open-market share purchases or sales reported in this filing.

Positive

  • None.

Negative

  • None.
Insider Germano Geno J
Role null
Type Security Shares Price Value
Grant/Award Stock Option 21,231 $0.00 --
Holdings After Transaction: Stock Option — 21,231 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 21,231 options Stock option grant to director Germano Geno J
Exercise price $30.76 per share Strike price for Harmony Biosciences common stock
Expiration date May 14, 2036 Option term end date
Vesting schedule 36 monthly installments Vesting begins June 14, 2026
Options held after grant 21,231 options Total derivative holdings following this transaction
Stock Option financial
"security_title: "Stock Option" related to Harmony Biosciences common stock"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
vesting financial
"The stock option shall vest in 36 equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Common Stock financial
"underlying_security_title: "Common Stock" as the underlying security"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Germano Geno J

(Last)(First)(Middle)
C/O HARMONY BIOSCIENCES HOLDINGS, INC.
630 W GERMANTOWN PIKE, SUITE 215

(Street)
PLYMOUTH MEETING PENNSYLVANIA 19462

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Harmony Biosciences Holdings, Inc. [ HRMY ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option$30.7605/14/2026A21,231 (1)05/14/2036Common Stock21,231$021,231D
Explanation of Responses:
1. The stock option shall vest in 36 equal monthly installments beginning on June 14, 2026.
/s/ Christian Ulrich, Attorney-in-Fact05/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Harmony Biosciences (HRMY) report for Germano Geno J?

Harmony Biosciences reported that director Germano Geno J received a grant of 21,231 stock options. These options relate to the company’s common stock and are part of his equity-based compensation, rather than an open-market purchase or sale of existing shares.

How many stock options were granted to Harmony Biosciences (HRMY) director Germano Geno J?

Germano Geno J was granted 21,231 stock options. The options give him the right to acquire Harmony Biosciences common stock at a fixed exercise price, subject to vesting over time as described in the award terms.

What is the exercise price of the new stock options at Harmony Biosciences (HRMY)?

The stock options granted to Germano Geno J have an exercise price of $30.76 per share. This means he can buy Harmony Biosciences common stock at $30.76 once the options vest, regardless of the market price at that time.

When do Germano Geno J’s Harmony Biosciences (HRMY) stock options vest?

The stock options begin vesting on June 14, 2026, in 36 equal monthly installments. This monthly vesting schedule spreads the award over three years, aligning the director’s incentives with the company’s longer-term performance and service period.

When do the newly granted Harmony Biosciences (HRMY) stock options expire?

The granted stock options expire on May 14, 2036. If Germano Geno J does not exercise the options by that expiration date, they will lapse and no longer provide the right to purchase Harmony Biosciences common shares at the set price.

Did Germano Geno J buy or sell Harmony Biosciences (HRMY) shares on the market?

No open-market share purchases or sales are reported in this Form 4. The filing only shows a grant of 21,231 stock options as compensation, not a transaction where existing Harmony Biosciences shares were bought or sold.